

#### **CONSOLIDATED FINANCIAL STATEMENTS**

**JUNE 30, 2020 AND 2019** 

CPAS/ADVISORS



# TABLE OF CONTENTS JUNE 30, 2020 AND 2019

	Page
Report of Independent Auditors	1
Consolidated Financial Statements	
Consolidated Balance Sheets	3
Consolidated Statements of Operations and Changes in Net Assets	5
Consolidated Statements of Cash Flows	6
Notes to Consolidated Financial Statements	7
Report of Independent Auditors on Internal Control Over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with	
Government Auditing Standards	35



Blue & Co., LLC / 500 N. Meridian Street, Suite 200 / Indianapolis, IN 46204 main 317.633.4705 fax 317.633.4889 email blue@blueandco.com

#### REPORT OF INDEPENDENT AUDITORS

Board of Directors Little Company of Mary Hospital of Indiana, Inc. and Affiliates Jasper, Indiana

We have audited the accompanying consolidated financial statements of Little Company of Mary Hospital of Indiana, Inc. and Affiliates (the "Corporation"), a wholly controlled subsidiary of the American Province of Little Company of Mary Sisters, which comprise the consolidated balance sheets as of June 30, 2020 and 2019, and the related consolidated statements of operations and changes in net assets, and cash flows for the years then ended, and the related notes to the consolidated financial statements.

#### Management's Responsibility for the Consolidated Financial Statements

Management is responsible for the preparation and fair presentation of these consolidated financial statements in accordance with accounting principles generally accepted in the United States of America; this includes the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

#### **Auditor's Responsibility**

Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We conducted our audits in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the consolidated financial statements. The procedures selected depend on the auditor's judgment, including the assessment of the risks of material misstatement of the consolidated financial statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control relevant to the entity's preparation and fair presentation of the consolidated financial statements in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the entity's internal control. Accordingly, we express no such opinion. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.

Board of Directors Little Company of Mary Hospital of Indiana, Inc. and Affiliates Jasper, Indiana

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

#### **Opinion**

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Corporation as of June 30, 2020 and 2019, and the results of its operations and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

#### **Change in Accounting Principles**

As discussed in Note 2 to the financial statements, effective July 1, 2019, the Corporation adopted Financial Accounting Standards Board (FASB) Accounting Standards Update (ASU) No. 2018-08, Clarifying the Scope and the Accounting Guidance for Contributions Received and Contributions Made and FASB ASU No. 2016-01, Financial Instruments — Overall (Subtopic) 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. Our opinion is not modified with respect to these matters.

#### Other Reporting Required by Government Auditing Standards

In accordance with *Government Auditing Standards*, we have also issued our report dated October 15, 2020, on our consideration of the Corporation's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements and other matters. The purpose of that report is to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the Corporation's internal control over financial reporting and compliance.

Blue & Co., LLC

Indianapolis, Indiana October 15, 2020

# CONSOLIDATED BALANCE SHEETS JUNE 30, 2020 AND 2019

#### **ASSETS**

	2020		2019	
Current assets				
Cash and cash equivalents	\$	63,750,373	\$ 41,314,701	
Investments		10,249,164	6,711,411	
Patient accounts receivable		21,213,756	24,556,391	
Other receivables		2,192,345	2,646,856	
Inventory and other current assets		5,318,488	5,780,084	
Pension asset		2,372,782	 -0-	
Total current assets		105,096,908	81,009,443	
Assets limited as to use, less current portion				
Board designated funds		88,737,264	87,520,597	
Trustee held, less current portion		812	93,182	
Donor restricted funds		3,483,399	1,899,217	
Investments held by Foundation		5,909,956	 5,508,359	
Total assets limited as to use		98,131,431	95,021,355	
Property and equipment				
Land and improvements		11,046,937	10,918,762	
Buildings and building equipment		121,562,028	121,009,807	
Furniture and equipment		103,337,152	98,776,970	
Construction in process		1,172,693	 -0-	
		237,118,810	230,705,539	
Less allowances for depreciation		151,252,230	141,994,975	
Total property and equipment, net		85,866,580	88,710,564	
Other assets				
Pension asset		-0-	2,372,782	
Other long-term assets		1,955,611	1,813,717	
Total assets	\$	291,050,530	\$ 268,927,861	

# CONSOLIDATED BALANCE SHEETS JUNE 30, 2020 AND 2019

#### **LIABILITIES AND NET ASSETS**

	2020		 2019	
Current liabilities		_		
Accounts payable	\$	5,167,920	\$ 4,965,841	
Accrued expenses and other current liabilities		19,481,807	17,440,073	
Estimated settlements due to third-party payors		12,880,723	2,126,391	
Current portion of long-term debt		2,011,102	2,019,409	
Total current liabilities		39,541,552	26,551,714	
Long-term liabilities				
Long-term debt, less current portion		44,963,675	 47,032,435	
Total long-term liabilities		44,963,675	47,032,435	
Total liabilities		84,505,227	73,584,149	
Net assets				
Without donor restrictions		203,061,904	193,444,495	
With donor restrictions		3,483,399	 1,899,217	
Total net assets		206,545,303	195,343,712	
Total liabilities and net assets	\$	291,050,530	\$ 268,927,861	

# CONSOLIDATED STATEMENTS OF OPERATIONS AND CHANGES IN NET ASSETS YEARS ENDED JUNE 30, 2020 AND 2019

Revenue and other support without donor restrictions         \$ 224,480,976         \$ 227,913,624           Patient service revenue         8,740,597         4,253,421           Total revenue and other support without donor restrictions         233,221,573         232,167,045           Expenses         105,714,473         102,527,128           Employee benefits         20,465,960         25,127,045           Supplies and drugs         37,378,709         36,665,781           Professional fees         9,509,588         8,527,157           Depreciation and amortization         12,221,044         12,692,583           Purchased services         10,904,048         9,786,514           Hospital assessment fee and healthy Indiana plan         10,075,294         9,842,451           Interest         2,296,008         2,386,008           Facility fees and leases         11,437,462         11,813,805           Other         6,663,550         6,561,124           Total expenses         226,666,136         225,929,596           Income from operations before pension termination         6,555,437         3,486,600           Nonoperating gains (losses)         2,655,386         2,845,393           Investment return, net         2,655,386         2,845,393           <			2020		2019
Other revenue and support Total revenue and other support without donor restrictions         8,740,597         4,253,421           Expenses         105,714,473         102,527,128           Employee benefits         20,465,960         25,127,045           Supplies and drugs         37,378,709         36,665,781           Professional fees         9,509,588         8,527,157           Depreciation and amortization         12,221,044         12,692,583           Purchased services         10,904,048         9,786,514           Hospital assessment fee and healthy Indiana plan         10,075,294         9,842,451           Interest         2,296,008         2,386,008           Facility fees and leases         11,437,462         11,813,805           Other         6,663,550         6,561,124           Total expenses         226,666,136         225,929,596           Income from operations before pension termination         6,555,437         3,486,600           Nonoperating gains (losses)         1         1         2         2         2         2         2         2         2         3         3,486,600         3         3         4         2         3         3         4         6         6         5         5         4		<b>+</b>	224 400 076	4	227.012.624
Total revenue and other support without donor restrictions		\$		<b>&gt;</b>	
Expenses         Salaries and wages         105,714,473         102,527,128         Employee benefits         20,465,960         25,127,045         Supplies and drugs         37,378,709         36,665,781         Professional fees         9,509,588         8,527,157         Depreciation and amortization         12,221,044         12,692,583         Purchased services         10,904,048         9,786,514         Hospital assessment fee and healthy Indiana plan         10,075,294         9,842,451         Interest         2,296,008         2,386,008         Facility fees and leases         11,437,462         11,813,805         Other         6,663,550         6,561,124         Total expenses         226,666,136         225,929,596         Income from operations before pension termination         6,555,437         6,237,449         Pension termination         -0         2,750,789         Pension termination         6,555,437         3,486,660         Nonoperating gains (losses)         Investment return, net         2,655,386         2,845,393         Anderon pension return return, net         2,655,386         2,845,393         Anderon pension return return, net         2,655,386         2,845,393         Anderon return return, net <td>···</td> <td></td> <td></td> <td></td> <td></td>	···				
Salaries and wages         105,714,473         102,527,128           Employee benefits         20,465,960         25,127,045           Supplies and drugs         37,378,709         36,665,781           Professional fees         9,509,588         8,527,157           Depreciation and amortization         12,221,044         12,692,583           Purchased services         10,904,048         9,786,514           Hospital assessment fee and healthy Indiana plan         10,075,294         9,842,451           Interest         2,296,008         2,386,008           Facility fees and leases         11,437,462         11,813,805           Other         6,663,550         6,561,124           Total expenses         226,666,136         225,929,596           Income from operations before pension termination         6,555,437         6,237,449           Pension termination         -0         2,750,789           Income from operations after pension termination         6,555,437         3,486,660           Nonoperating gains (losses)         1         419,975         335,769           Investment return, net         2,655,386         2,845,393         3,181,162           Excess of revenues over expenses         9,241,431         6,667,822           Other chan			233,221,313		232,107,043
Employee benefits         20,465,960         25,127,045           Supplies and drugs         37,378,709         36,665,781           Professional fees         9,509,588         8,527,157           Depreciation and amortization         12,221,044         12,692,583           Purchased services         10,904,048         9,786,514           Hospital assessment fee and healthy Indiana plan         10,075,294         9,842,451           Interest         2,296,008         2,386,008           Facility fees and leases         11,437,462         11,813,805           Other         6,63,550         6,561,124           Total expenses         226,666,136         225,929,596           Income from operations before pension termination         6,555,437         6,237,449           Pension termination         -0-         2,750,789           Investment return, net         2,655,386         2,845,393           Net unrealized losses on investments         (389,367)         -0-           Other         419,975         335,769           Total nonoperating gains, net         2,685,994         3,181,162           Excess of revenues over expenses         9,241,431         6,667,822           Other changes in net assets without donor restrictions         -0-	•		105 71 1 170		100 507 100
Supplies and drugs         37,378,709         36,665,781           Professional fees         9,509,588         8,527,157           Depreciation and amortization         12,221,044         12,692,583           Purchased services         10,904,048         9,786,514           Hospital assessment fee and healthy Indiana plan         10,075,294         9,842,451           Interest         2,296,008         2,386,008           Facility fees and leases         11,437,462         11,813,805           Other         6,663,550         6,561,124           Total expenses         226,666,136         225,929,596           Income from operations before pension termination         6,555,437         6,237,449           Pension termination         -0         2,750,789           Income from operations after pension termination         6,555,437         3,486,660           Nonoperating gains (losses)         3,486,660           Nonoperating gains (losses)         3,486,660           Nonoperating gains (losses)         3,486,660           Nonoperating gains (losses)         2,455,386         2,845,393           Net unrealized losses on investments         389,3671         -0           Other         419,975         335,769           Total nonoperating gains, n					
Professional fees         9,509,588         8,527,157           Depreciation and amortization         12,221,044         12,692,583           Purchased services         10,904,048         9,786,514           Hospital assessment fee and healthy Indiana plan         10,075,294         9,842,451           Interest         2,296,008         2,386,008           Facility fees and leases         11,437,462         11,813,805           Other         6,663,550         6,561,124           Total expenses         226,666,136         2225,929,596           Income from operations before pension termination         6,555,437         6,237,449           Pension termination         -0-         2,750,789           Income from operations after pension termination         6,555,437         3,486,660           Nonoperating gains (losses)         1         4,997         33,486,660           Nonoperating gains (losses)         2,655,386         2,845,393         -0-           Notal mealized losses on investments         389,367         -0-         -0-           Other         419,975         335,769         335,769           Total nonoperating gains, net         2,685,994         3,181,162         2,685,994         3,181,162           Excess of revenues over expenses </td <td>·</td> <td></td> <td></td> <td></td> <td></td>	·				
Depreciation and amortization         12,221,044         12,692,583           Purchased services         10,904,048         9,786,514           Hospital assessment fee and healthy Indiana plan Interest         2,296,008         2,386,008           Facility fees and leases         11,437,462         11,813,805           Other         6,663,550         6,561,124           Total expenses         226,666,136         2225,929,596           Income from operations before pension termination         6,555,437         6,237,449           Pension termination         -0-         2,750,789           Income from operations after pension termination         6,555,437         3,486,660           Nonoperating gains (losses)         Investment return, net         2,655,386         2,845,393           Net unrealized losses on investments         389,367         -0-           Other         419,975         335,769           Total nonoperating gains, net         2,685,994         3,181,162           Excess of revenues over expenses         9,241,431         6,667,822           Other changes in net assets without donor restrictions         -0-         1,610,137           Net assets released from restriction         375,978         899,673           Pension related changes other than net periodic pension cost <td>Supplies and drugs</td> <td></td> <td>37,378,709</td> <td></td> <td>36,665,781</td>	Supplies and drugs		37,378,709		36,665,781
Purchased services         10,904,048         9,786,514           Hospital assessment fee and healthy Indiana plan Interest         2,296,008         2,386,008           Facility fees and leases         11,437,462         11,813,805           Other         6,663,550         6,561,124           Total expenses         226,666,136         225,929,596           Income from operations before pension termination         6,555,437         6,237,449           Pension termination         -0-         2,750,789           Income from operations after pension termination         6,555,437         3,486,660           Nonoperating gains (losses)         3,486,660           Investment return, net         2,655,386         2,845,393           Net unrealized losses on investments         (389,367)         -0-           Other         419,975         335,769           Total nonoperating gains, net         2,685,994         3,181,162           Excess of revenues over expenses         9,241,431         6,667,822           Other changes in net assets without donor restrictions         -0-         1,610,137           Net aurealized gains on investments         -0-         1,610,137           Pension related changes other than net periodic pension cost         -0-         2,589,169			9,509,588		8,527,157
Hospital assessment fee and healthy Indiana plan   10,075,294   9,842,451     Interest   2,296,008   2,386,008     Facility fees and leases   11,437,462   11,813,805     Other   6,663,550   6,561,124     Total expenses   226,666,136   225,929,596     Income from operations before pension termination   6,555,437   6,237,449     Pension termination   -0- 2,750,789     Income from operations after pension termination   6,555,437   3,486,660     Nonoperating gains (losses)     Investment return, net   2,655,386   2,845,393     Net unrealized losses on investments   (389,367)   -0- (2,685,994   3,181,162     Excess of revenues over expenses   9,241,431   6,667,822     Other changes in net assets without donor restrictions   375,978   899,673     Net assets released from restriction   375,978   899,673     Changes in net assets without donor restrictions   9,617,409   11,766,801     Net assets released from restriction   (375,978)   (899,673)     Changes in net assets with donor restrictions   1,960,160   723,149     Net assets released from restriction   (375,978)   (899,673)     Changes in net assets with donor restrictions   1,584,182   (176,524)     Changes in net assets with donor restrictions   1,584,182   (176,524)     Changes in net assets with donor restrictions   1,584,182   (176,524)     Changes in net assets with donor restrictions   1,584,182   (176,524)     Changes in net assets with donor restrictions   1,584,182   (176,524)     Changes in net assets with donor restrictions   1,584,182   (176,524)     Changes in net assets with donor restrictions   1,584,182   (176,524)     Changes in net assets with donor restrictions   1,584,182   (176,524)     Changes in net assets with donor restrictions   1,584,182   (176,524)     Changes in net assets with donor restrictions   1,584,182   (176,524)     Changes in net assets with donor restrictions   1,584,182   (176,524)     Changes in net assets with donor restrictions   1,584,182   (176,524)     Changes in net assets with donor restrictions   1,584,182   (176	Depreciation and amortization		12,221,044		12,692,583
Interest   2,296,008   2,386,008   Facility fees and leases   11,437,462   11,813,805   Chter   6,663,550   6,561,124   Total expenses   226,666,136   225,929,596   Income from operations before pension termination   6,555,437   6,237,449   Changes in net assets with donor restrictions   2,655,347   3,486,660   Changes in net assets with donor restrictions   2,6655,386   2,845,393   Changes in net assets with donor restrictions   2,6655,386   2,845,393   Changes in net assets with donor restrictions   3,241,431   6,667,822   Changes in net assets without donor restrictions   3,257,978   2,241,431   2,2685,994   3,181,162   2,2685,994   3,181,162   2,2685,994   3,181,162   2,2685,994   3,181,162   2,2685,994   3,181,162   2,2685,994   3,181,162   2,2685,994   3,181,162   2,2685,994   3,181,162   2,2685,994   3,181,162   2,2685,994   3,181,162   2,2685,994   3,181,162   2,2685,994   3,181,162   2,2685,994   3,181,162   2,2685,994   3,181,162   2,2685,994   3,181,162   2,2685,994   3,181,162   2,2685,994   3,181,162   2,2685,994   3,181,162   2,2685,994   3,181,162   2,2685,994   3,181,162   2,2685,994   3,181,162   2,2685,994   3,181,162   2,2685,994   3,181,162   2,2685,994   3,181,162   2,2685,994   3,181,162   2,2685,994   3,181,162   2,2685,994   3,181,162   2,2685,994   3,181,162   2,2685,994   3,181,162   2,2685,994   3,181,162   2,2685,994   3,181,162   2,2685,994   3,181,162   2,2685,994   3,181,162   2,2685,994   3,181,162   2,2685,994   3,181,162   2,2685,994   3,181,162   2,2685,994   3,181,162   2,2685,994   3,181,162   2,2685,994   3,181,162   2,2685,994   3,181,162   2,2685,994   3,181,162   2,2685,994   3,181,162   2,2685,994   3,181,162   2,2685,994   3,181,162   2,2685,994   3,181,162   2,2685,994   3,181,162   2,2685,994   3,181,162   2,2685,994   3,181,162   2,2685,994   3,181,162   2,2685,994   3,181,162   2,2685,994   3,181,162   2,2685,994   3,181,162   2,2685,994   3,181,162   2,2685,994   3,181,162   2,2685,994   3,181,162   2,2685,994   3,181,162   2,2685,994   3,181,162   2,2685,994	Purchased services		10,904,048		9,786,514
Facility fees and leases         11,437,462         11,813,805           Other         6,663,550         6,561,124           Total expenses         226,666,136         225,929,596           Income from operations before pension termination         6,555,437         6,237,449           Pension termination         -0-         2,750,789           Income from operations after pension termination         6,555,437         3,486,660           Nonoperating gains (losses)         1         2,655,386         2,845,393           Net unrealized losses on investments         (389,367)         -0-           Other         419,975         335,769           Total nonoperating gains, net         2,685,994         3,181,162           Excess of revenues over expenses         9,241,431         6,667,822           Other changes in net assets without donor restrictions         -0-         1,610,137           Net assets released from restriction         375,978         899,673           Pension related changes other than net periodic pension cost         -0-         2,589,169           Changes in net assets without donor restrictions         9,617,409         11,766,801           Net assets with donor restrictions         1,960,160         723,149           Net assets released from restriction         (	Hospital assessment fee and healthy Indiana plan		10,075,294		9,842,451
Other         6,663,550         6,561,124           Total expenses         226,666,136         225,929,596           Income from operations before pension termination         6,555,437         6,237,449           Pension termination         -0-         2,750,789           Income from operations after pension termination         6,555,437         3,486,660           Nonoperating gains (losses)         2,655,386         2,845,393           Investment return, net         2,655,386         2,845,393           Net unrealized losses on investments         (389,367)         -0-           Other         419,975         335,769           Total nonoperating gains, net         2,685,994         3,181,162           Excess of revenues over expenses         9,241,431         6,667,822           Other changes in net assets without donor restrictions         -0-         1,610,137           Net assets released from restriction         375,978         899,673           Pension related changes other than net periodic pension cost         -0-         2,589,169           Changes in net assets without donor restrictions         9,617,409         11,766,801           Net assets with donor restrictions         1,960,160         723,149           Net assets released from restriction         (375,978)         <	Interest		2,296,008		2,386,008
Total expenses         226,666,136         225,929,596           Income from operations before pension termination         6,555,437         6,237,449           Pension termination         -0-         2,750,789           Income from operations after pension termination         6,555,437         3,486,660           Nonoperating gains (losses)         Use 55,386         2,845,393           Investment return, net         2,655,386         2,845,393           Net unrealized losses on investments         (389,367)         -0-           Other         419,975         335,769           Total nonoperating gains, net         2,685,994         3,181,162           Excess of revenues over expenses         9,241,431         6,667,822           Other changes in net assets without donor restrictions         -0-         1,610,137           Net assets released from restriction         375,978         899,673           Pension related changes other than net periodic pension cost         -0-         2,589,169           Changes in net assets without donor restrictions         9,617,409         11,766,801           Net assets with donor restrictions         1,960,160         723,149           Net assets released from restriction         (375,978)         (899,673)           Changes in net assets with donor restrictions<	Facility fees and leases		11,437,462		11,813,805
Income from operations before pension termination         6,555,437         6,237,449           Pension termination         -0-         2,750,789           Income from operations after pension termination         6,555,437         3,486,660           Nonoperating gains (losses)         Investment return, net         2,655,386         2,845,393           Net unrealized losses on investments         (389,367)         -0-           Other         419,975         335,769           Total nonoperating gains, net         2,685,994         3,181,162           Excess of revenues over expenses         9,241,431         6,667,822           Other changes in net assets without donor restrictions         -0-         1,610,137           Net assets released from restriction         375,978         899,673           Pension related changes other than net periodic pension cost         -0-         2,589,169           Changes in net assets without donor restrictions         9,617,409         11,766,801           Net assets with donor restrictions         1,960,160         723,149           Net assets released from restriction         (375,978)         (899,673)           Changes in net assets with donor restrictions         1,584,182         (176,524)           Changes in net assets         11,201,591         11,590,277	Other		6,663,550		6,561,124
Pension termination         -0-         2,750,789           Income from operations after pension termination         6,555,437         3,486,660           Nonoperating gains (losses)         3         486,600           Investment return, net         2,655,386         2,845,393           Net unrealized losses on investments         (389,367)         -0-           Other         419,975         335,769           Total nonoperating gains, net         2,685,994         3,181,162           Excess of revenues over expenses         9,241,431         6,667,822           Other changes in net assets without donor restrictions         -0-         1,610,137           Net assets released from restriction         375,978         899,673           Pension related changes other than net periodic pension cost         -0-         2,589,169           Changes in net assets without donor restrictions         9,617,409         11,766,801           Net assets with donor restrictions         1,960,160         723,149           Net assets released from restriction         (375,978)         (899,673)           Changes in net assets with donor restrictions         1,584,182         (176,524)           Changes in net assets         11,201,591         11,590,277           Net assets         89,673         11,2	Total expenses		226,666,136		225,929,596
Income from operations after pension termination   6,555,437   3,486,660	Income from operations before pension termination		6,555,437		6,237,449
Nonoperating gains (losses)           Investment return, net         2,655,386         2,845,393           Net unrealized losses on investments         (389,367)         -0-           Other         419,975         335,769           Total nonoperating gains, net         2,685,994         3,181,162           Excess of revenues over expenses         9,241,431         6,667,822           Other changes in net assets without donor restrictions           Net unrealized gains on investments         -0-         1,610,137           Net assets released from restriction         375,978         899,673           Pension related changes other than net periodic pension cost         -0-         2,589,169           Changes in net assets without donor restrictions         9,617,409         11,766,801           Net assets with donor restrictions           Contributions         1,960,160         723,149           Net assets released from restriction         (375,978)         (899,673)           Changes in net assets with donor restrictions         1,584,182         (176,524)           Changes in net assets with donor restrictions         1,584,182         (176,524)           Changes in net assets         11,201,591         11,590,277           Net assets	Pension termination		-0-		2,750,789
Investment return, net         2,655,386         2,845,393           Net unrealized losses on investments         (389,367)         -0-           Other         419,975         335,769           Total nonoperating gains, net         2,685,994         3,181,162           Excess of revenues over expenses         9,241,431         6,667,822           Other changes in net assets without donor restrictions         -0-         1,610,137           Net unrealized gains on investments         -0-         1,610,137           Net assets released from restriction         375,978         899,673           Pension related changes other than net periodic pension cost         -0-         2,589,169           Changes in net assets without donor restrictions         9,617,409         11,766,801           Net assets with donor restrictions         1,960,160         723,149           Net assets released from restriction         (375,978)         (899,673)           Changes in net assets with donor restrictions         1,584,182         (176,524)           Changes in net assets         11,201,591         11,590,277           Net assets           Beginning of year         195,343,712         183,753,435	Income from operations after pension termination		6,555,437		3,486,660
Investment return, net         2,655,386         2,845,393           Net unrealized losses on investments         (389,367)         -0-           Other         419,975         335,769           Total nonoperating gains, net         2,685,994         3,181,162           Excess of revenues over expenses         9,241,431         6,667,822           Other changes in net assets without donor restrictions         -0-         1,610,137           Net unrealized gains on investments         -0-         1,610,137           Net assets released from restriction         375,978         899,673           Pension related changes other than net periodic pension cost         -0-         2,589,169           Changes in net assets without donor restrictions         9,617,409         11,766,801           Net assets with donor restrictions         1,960,160         723,149           Net assets released from restriction         (375,978)         (899,673)           Changes in net assets with donor restrictions         1,584,182         (176,524)           Changes in net assets         11,201,591         11,590,277           Net assets           Beginning of year         195,343,712         183,753,435	Nonoperating gains (losses)				
Other         419,975         335,769           Total nonoperating gains, net         2,685,994         3,181,162           Excess of revenues over expenses         9,241,431         6,667,822           Other changes in net assets without donor restrictions           Net unrealized gains on investments         -0-         1,610,137           Net assets released from restriction         375,978         899,673           Pension related changes other than net periodic pension cost         -0-         2,589,169           Changes in net assets without donor restrictions         9,617,409         11,766,801           Net assets with donor restrictions           Contributions         1,960,160         723,149           Net assets released from restriction         (375,978)         (899,673)           Changes in net assets with donor restrictions         1,584,182         (176,524)           Changes in net assets         11,201,591         11,590,277           Net assets           Beginning of year         195,343,712         183,753,435			2,655,386		2,845,393
Total nonoperating gains, net         2,685,994         3,181,162           Excess of revenues over expenses         9,241,431         6,667,822           Other changes in net assets without donor restrictions           Net unrealized gains on investments         -0-         1,610,137           Net assets released from restriction         375,978         899,673           Pension related changes other than net periodic pension cost         -0-         2,589,169           Changes in net assets without donor restrictions         9,617,409         11,766,801           Net assets with donor restrictions         1,960,160         723,149           Net assets released from restriction         (375,978)         (899,673)           Changes in net assets with donor restrictions         1,584,182         (176,524)           Changes in net assets         11,201,591         11,590,277           Net assets           Beginning of year         195,343,712         183,753,435	Net unrealized losses on investments		(389,367)		-0-
Excess of revenues over expenses       9,241,431       6,667,822         Other changes in net assets without donor restrictions       -0- 1,610,137         Net unrealized gains on investments       -0- 1,610,137         Net assets released from restriction       375,978       899,673         Pension related changes other than net periodic pension cost       -0- 2,589,169         Changes in net assets without donor restrictions       9,617,409       11,766,801         Net assets with donor restrictions       1,960,160       723,149         Net assets released from restriction       (375,978)       (899,673)         Changes in net assets with donor restrictions       1,584,182       (176,524)         Changes in net assets       11,201,591       11,590,277         Net assets         Beginning of year       195,343,712       183,753,435	Other		419,975		335,769
Other changes in net assets without donor restrictionsNet unrealized gains on investments-0-1,610,137Net assets released from restriction375,978899,673Pension related changes other than net periodic pension cost-0-2,589,169Changes in net assets without donor restrictions9,617,40911,766,801Net assets with donor restrictions1,960,160723,149Net assets released from restriction(375,978)(899,673)Changes in net assets with donor restrictions1,584,182(176,524)Changes in net assets11,201,59111,590,277Net assets195,343,712183,753,435	Total nonoperating gains, net		2,685,994		3,181,162
Net unrealized gains on investments         -0-         1,610,137           Net assets released from restriction         375,978         899,673           Pension related changes other than net periodic pension cost         -0-         2,589,169           Changes in net assets without donor restrictions         9,617,409         11,766,801           Net assets with donor restrictions         1,960,160         723,149           Net assets released from restriction         (375,978)         (899,673)           Changes in net assets with donor restrictions         1,584,182         (176,524)           Changes in net assets         11,201,591         11,590,277           Net assets         195,343,712         183,753,435	Excess of revenues over expenses		9,241,431		6,667,822
Net assets released from restriction       375,978       899,673         Pension related changes other than       -0-       2,589,169         Changes in net assets without donor restrictions       9,617,409       11,766,801         Net assets with donor restrictions       1,960,160       723,149         Net assets released from restriction       (375,978)       (899,673)         Changes in net assets with donor restrictions       1,584,182       (176,524)         Changes in net assets       11,201,591       11,590,277         Net assets         Beginning of year       195,343,712       183,753,435	Other changes in net assets without donor restrictions				
Pension related changes other than net periodic pension cost         -0-         2,589,169           Changes in net assets without donor restrictions         9,617,409         11,766,801           Net assets with donor restrictions         1,960,160         723,149           Net assets released from restriction         (375,978)         (899,673)           Changes in net assets with donor restrictions         1,584,182         (176,524)           Changes in net assets         11,201,591         11,590,277           Net assets           Beginning of year         195,343,712         183,753,435			-0-		1,610,137
net periodic pension cost         -0-         2,589,169           Changes in net assets without donor restrictions         9,617,409         11,766,801           Net assets with donor restrictions         1,960,160         723,149           Net assets released from restriction         (375,978)         (899,673)           Changes in net assets with donor restrictions         1,584,182         (176,524)           Changes in net assets         11,201,591         11,590,277           Net assets           Beginning of year         195,343,712         183,753,435	Net assets released from restriction		375,978		899,673
Changes in net assets without donor restrictions       9,617,409       11,766,801         Net assets with donor restrictions       1,960,160       723,149         Net assets released from restriction       (375,978)       (899,673)         Changes in net assets with donor restrictions       1,584,182       (176,524)         Changes in net assets       11,201,591       11,590,277         Net assets       195,343,712       183,753,435	Pension related changes other than				
Net assets with donor restrictions           Contributions         1,960,160         723,149           Net assets released from restriction         (375,978)         (899,673)           Changes in net assets with donor restrictions         1,584,182         (176,524)           Changes in net assets         11,201,591         11,590,277           Net assets           Beginning of year         195,343,712         183,753,435	net periodic pension cost		-0-	_	2,589,169
Contributions         1,960,160         723,149           Net assets released from restriction         (375,978)         (899,673)           Changes in net assets with donor restrictions         1,584,182         (176,524)           Changes in net assets         11,201,591         11,590,277           Net assets           Beginning of year         195,343,712         183,753,435	Changes in net assets without donor restrictions		9,617,409		11,766,801
Net assets released from restriction         (375,978)         (899,673)           Changes in net assets with donor restrictions         1,584,182         (176,524)           Changes in net assets         11,201,591         11,590,277           Net assets         8eginning of year         195,343,712         183,753,435	Net assets with donor restrictions				
Net assets released from restriction         (375,978)         (899,673)           Changes in net assets with donor restrictions         1,584,182         (176,524)           Changes in net assets         11,201,591         11,590,277           Net assets           Beginning of year         195,343,712         183,753,435			1,960,160		723,149
Changes in net assets with donor restrictions       1,584,182       (176,524)         Changes in net assets       11,201,591       11,590,277         Net assets         Beginning of year       195,343,712       183,753,435	Net assets released from restriction				•
Net assets         195,343,712         183,753,435	Changes in net assets with donor restrictions				
Beginning of year         195,343,712         183,753,435	Changes in net assets		11,201,591		11,590,277
	Net assets				
End of year \$ 206.545.303 \$ 195.343.712	Beginning of year		195,343,712		183,753,435
<u> </u>	End of year	\$	206,545,303	\$	195,343,712

#### CONSOLIDATED STATEMENTS OF CASH FLOWS YEARS ENDED JUNE 30, 2020 AND 2019

	2020		2019	
Operating activities				
Changes in net assets	\$	11,201,591	\$	11,590,277
Adjustments to reconcile change in net assets				
to net cash from operating activities:				
Restricted contributions		(1,960,160)		(723,149)
Depreciation and amortization		12,221,044		12,692,583
Net realized and unrealized (gain) losses on investments		318,637		(1,720,360)
Amortization of original issue (premiums) discounts, net		(58,302)		(58,302)
Loss on the disposal of assets		19,220		26,452
Changes in operating assets and liabilities:				
Patient accounts receivable		3,342,635		(1,172,781)
Other current assets		916,107		714,560
Other long-term assets		(182,608)		(181,536)
Accounts payable		(314,921)		82,598
Accrued expenses and other current liabilities		2,041,734		4,264,523
Estimated settlements due to third-party payors		10,754,332		292,642
Pension asset		-0-		273,441
Net cash flows from operating activities		38,299,309		26,080,948
Investing activities				
Additions to property and equipment		(8,838,566)		(8,519,226)
Proceeds from disposal of property and equipment		-0-		2,906
Change in investments and assets limited as to use		(6,966,466)		(2,300,898)
Net cash flows from investing activities		(15,805,032)		(10,817,218)
Financing activities				
Restricted contributions		1,960,160		723,149
Repayments of long-term debt		(2,018,765)		(1,923,616)
Net cash flows from financing activities		(58,605)		(1,200,467)
Net change in cash and cash equivalents		22,435,672		14,063,263
Cash and cash equivalents				
Beginning of year		41,314,701		27,251,438
End of year	\$	63,750,373	\$	41,314,701
Supplemental cash flows information				
Property and equipment included in accounts payable	\$	517,000	\$	422,000

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2020 AND 2019

#### 1. ORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES

#### **Nature of Operations**

The mission of Little Company of Mary Hospital of Indiana, Inc. d/b/a Memorial Hospital and Health Care Center, Inc. (Corporation) is as follows:

Christ's healing mission of compassion empowers us to be for others through quality and excellence.

The Corporation is a subsidiary of and operates under the auspices of the American Province of The Little Company of Mary Sisters (American Province). The American Province is a religious community of the Roman Catholic Church, which operates health care facilities in the United States and certain other countries. The Board of Directors of the Corporation is appointed by the members of the Provincial Council of the American Province. The Corporation operates a general primary acute care hospital located in Jasper, Indiana.

#### Principles of Consolidation

The consolidated financial statements include the accounts of the Corporation and its wholly controlled affiliates, Memorial Hospital Foundation, Inc. (Foundation), and Barrett Health Corporation of Southwestern Indiana, LLC (Barrett). Transactions deemed by management to be ongoing, major, or central to the provision of health care services are reported as revenues and expenses. Peripheral or incidental transactions are reported as nonoperating gains and losses. Nonoperating gains and losses include investment income, realized gains and losses on investments, gains or losses on the sale or disposal of property and equipment, and other gains and losses.

Significant intercompany accounts and transactions have been eliminated in the consolidated financial statements.

#### **Use of Estimates**

The preparation of the consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, including the allowance for estimated uncollectible accounts and estimated third-party payor settlements, pension asset and liability, and disclosure of contingent assets and liabilities at the date of the consolidated financial statements. Estimates also affect the reported amounts of revenues and expenses during the reporting period and could differ from actual results.

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2020 AND 2019

#### **Charity Care and Community Benefit**

Patients are provided care regardless of their ability to pay and charity services are provided in accordance with charity care policies of the Corporation. These policies define charity services as those services for which no payment is anticipated and are based on federal poverty income levels and certain other factors. Because collection of amounts determined to qualify as charity care is not pursued, such amounts are not reported as revenue. The Corporation did not change its charity care policies during the year.

Of the Corporation's total expenses reported within the consolidated statements of operations and changes in net assets, an estimated \$1,467,000 and \$1,253,000 arose from providing services to charity patients during 2020 and 2019, respectively.

The estimated costs of providing charity services are based on a calculation which applies a ratio of costs to charges to the gross uncompensated charges associated with providing care to charity patients. The ratio of cost to charges is calculated based on the Corporation's total expenses divided by gross patient service revenue.

#### Cash Equivalents

All highly liquid instruments with an original maturity of 90 days or less excluding investments and assets limited as to use are considered to be cash equivalents. Cash equivalents consist primarily of short-term certificates of deposit and money market funds. The Corporation maintains its cash in accounts, which at times may exceed federally insured limits.

The Corporation has not experienced any losses in such accounts and believes that it is not exposed to any significant credit risk on cash and cash equivalents.

#### <u>Investments</u>

The Corporation invests in certain fixed income securities in order to enhance the return on funds available in current operations as needed. Included in these funds are cash equivalents, U.S. government obligations, and corporate obligations.

#### Patient Accounts Receivable

Patient accounts receivable are reported at the amounts that reflects the consideration which the Corporation expects to be entitled in exchange for providing patient care, as further described in Note 3.

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2020 AND 2019

Patient accounts receivable can be impacted by the effectiveness of the Corporation's collection efforts. Additionally, significant changes in payor mix, business office operations, economic conditions or trends in federal and state governmental healthcare coverage could affect the net realizable value of accounts receivable. The Corporation also continually reviews the net realizable value of accounts receivable by monitoring historical cash collections as a percentage of trailing net operating revenues, as well as by analyzing current period net revenue and admissions by payor classification, aged accounts receivable by payor, days revenue outstanding, the composition of self-pay receivables between pure self-pay patients and the patient responsibility portion of third-party insured receivables and the impact of recent acquisitions and dispositions.

Final settlements for some payors and programs are subject to adjustment based on administrative review and audit by third parties. As a result of these final settlements, the Corporation has recorded amounts due to third-party.

Given the current regulatory and reimbursement environment, there can be no assurances that adequate reimbursement levels will continue to be available for the services provided by the Corporation. Significant limits on the scope of services reimbursed and on reimbursement rates and fees could have a material adverse effect on the Corporation's financial condition, results of operations and cash flows.

The Corporation is primarily located in Jasper, Indiana. The Corporation grants credit without collateral to its patients, most of who are local residents and are insured under third-party payor agreements. The concentration of net patient accounts receivables from patients and third-party payors as of June 30, 2020 and 2019 is as follows:

	2020	2019
Medicare	25%	24%
Medicaid	8%	10%
Blue Cross	12%	12%
Commercial	31%	31%
Self-pay	24%	23%
	100%	100%

#### **Contract Costs**

The Corporation has applied the practical expedient provided by Financial Accounting Standards Board (FASB) Accounting Standards Update (ASU) 340-40-25-4 and all incremental customer contract acquisition costs are expensed as they are incurred, as the amortization period of the asset that the Corporation otherwise would have recognized is one year or less in duration.

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2020 AND 2019

#### Other Receivables

Other receivables consist mainly of physician loans that are expected to be forgiven or received within the period of one year.

#### **Inventory and Other Current Assets**

Inventory and other current assets consist primarily of pharmaceutical and medical supply inventories and prepaid expenses. Inventory is valued at the lower of cost or net realizable value with cost being determined on the first-in, first-out (FIFO) method. Inventory at year-end consists mainly of pharmaceuticals and medical supplies.

#### Assets Limited as to Use and Investment Income

Nonparticipating certificates of deposit, demand deposits and similar negotiable instruments that are not reported as cash and cash equivalents are reported as investments at contract value, which approximates fair value. Marketable debt, US Government and government agency obligations and common stocks are reported at fair value. US Government and government agency obligations are defined as securities backed by the full faith and credit of the United States Treasury or fully insured or guaranteed by the United States or any United States government agency. Mutual funds are reported at fair value based on the fund's market price. Donated investments are reported at fair value at the date of receipt. Dividends, interest income and realized gains (losses) on sales of investments are recorded as nonoperating investment gains (losses) while unrealized gains on investments are reported as other changes in net assets without donor restrictions in the consolidated statements of operations and changes in net assets. Interest income is recorded on the accrual basis. Dividends are recorded on the ex-dividend date.

Board designated investments limited as to use consist of short-term investments (principally money market mutual funds), US Government and government agency obligations, marketable debt securities, common stocks, and mutual funds. Investments are generally reported at fair value.

Board designated investments limited as to use represent certain funds from operations, investments held by the Foundation, donor restricted funds and other sources designated by the Board of Directors of the Corporation to be used to fund future capital asset replacements, for the retirement of certain long-term debt, or for other purposes.

Investments held by trustee have been established as required by terms of the various bond agreements. Such funds are to be used for payment of principal and interest, replacement or construction of property and equipment, and cash reserves. Funds held for obligations classified as current liabilities are reported as current assets.

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2020 AND 2019

#### Property and Equipment and Depreciation

Property and equipment are stated at cost, or if donated, at fair value at the date of donation, and include expenditures for new additions and repairs which substantially increase the useful lives of existing property and equipment. Maintenance repairs and minor renewals are expensed as incurred. When properties are retired or otherwise disposed of, the related cost and accumulated depreciation are removed from the accounts and any resulting gain or loss for the period is recognized. Provisions for depreciation of property and equipment are computed using the straight-line method based upon the estimated useful lives of the assets, which range from 2 to 40 years.

#### Financial Statement Presentation and Net Assets

The accompanying consolidated financial statements have been prepared on the accrual basis, and have been prepared with a focus on the entity as a whole. Net assets, support, revenues, gains, and losses are classified based on the existence or absence of donor restrictions.

Net assets with donor restrictions are those assets whose use by the Corporation has been limited by donors for capital projects or for a specific time or purpose. The primary projects and purposes relate to the cancer center, medication program and palliative care.

When donor restrictions expire, net assets with donor restrictions are reclassified to net assets without donor restrictions and reported in the consolidated statement of operations and changes in net assets as net assets released from restriction. The net assets released from restrictions for 2020 and 2019 primarily consist of funds for various capital projects. Resources arising from the results of operations or assets set aside by the Board of Directors are not considered to be with donor restrictions.

#### **Compensated Absences**

The Corporation's policy on compensated absences (which include vacation, holidays and a personal day) allows full time employees and regular part time employees to accrue days off, to a maximum of 240 hours. Compensated absences are accrued when incurred and reported as a liability on the consolidated balance sheet.

#### **Contributions and Support**

The Corporation recognizes contributions when cash, securities or other assets; an unconditional promise to give; or a notification of a beneficial interest is received. Conditional promises to give - that is, those with a measurable performance or other barrier and a right of return - are not recognized until the conditions on which they depend have been met. The Corporation did not have any refundable advances at June 30, 2020 and 2019.

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2020 AND 2019

See Note 13 for additional information surrounding support.

#### **Advertising Costs**

Advertising costs are expenses as incurred. Total advertising expense for 2020 and 2019 was approximately \$262,000 and \$278,000, respectively.

#### Performance Indicator

The consolidated statements of operations and changes in net assets include a performance indicator, excess of revenues over expenses. Changes in net assets without donor restrictions, which are excluded from excess of revenues over expenses, consistent with industry practice for 2020, include pension related changes other than net periodic pension cost and contributions of long-lived assets and certain other items. Additionally in 2019, unrealized gains and losses on all other than trading securities were excluded from the performance indicator.

#### **Medical Malpractice**

The Corporation purchases professional and general liability insurance to cover medical malpractice claims. There are known claims and incidents that may result in the assertion of additional claims, as well as claims from unknown incidents that may be asserted arising from services provided to patients.

The Indiana Medical Malpractice Act, IC 34-18 (the Act) provides a maximum recovery of \$1,800,000 for an occurrence of malpractice and provided a maximum recovery of \$1,650,000 prior to July 1, 2019. The Act requires the Corporation to maintain medical malpractice liability insurance in the amount of at least \$500,000 per occurrence (\$10,000,000 in the annual aggregate). Prior to July 1, 2019, the Act required the Corporation to maintain medical malpractice liability insurance in the amount of at least \$400,000 per occurrence (\$12,000,000 in the annual aggregate). The Act also requires the Corporation to pay a surcharge to the State Patient's Compensation Fund (the Fund). The Fund is used to pay medical malpractice claims in excess of per occurrence and the annual aggregate amounts as noted above, under certain terms and conditions. No accrual for possible losses attributable to incidents that may have occurred but that have not been identified has been made because the amount, if any, is not reasonably estimable.

The Fund is on a claims-made basis and as long as this coverage is continuous or replaced with equivalent insurance, claims based on occurrences during its term but reported subsequently will be insured.

Accounting principles generally accepted in the United States of America require a health care provider to accrue the expense of its share of malpractice claim costs, if any, for any reported and unreported incidents of potential improper professional service occurring during the year by

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2020 AND 2019

estimating the probable ultimate costs of the incidents. Based upon the Corporation's claim experience, no such accrual has been made. It is reasonably possible that this estimate could change materially in the near term.

#### Pension Plan

Effective October 31, 2017, the Corporation's Board of Directors elected to terminate the defined benefit plan and all obligations were settled prior to June 30, 2019. Previously, the Corporation's defined benefit pension plan covered substantially all employees. The benefits were based on years of service and each employee's compensation during the years of employment. Contributions were based on a seven-year amortization of any shortfall determined by comparing the funding target liability to the actuarial value of assets.

#### **Income Taxes**

The Corporation and Foundation are organized as not-for-profit corporations under Section 501(c) (3) of the United States Internal Revenue Code. The exemption is on all income except unrelated business income as noted under Section 511 of the Internal Revenue Code. Internal Revenue Code Section 513(a) defines an unrelated trade or business of an exempt organization as any trade or business which is not substantially related to the exercise or performance of its exempt purpose. As such, the Corporation and Foundation are generally exempt from income taxes. However, the Corporation and Foundation are required to file Federal Form 990 – Return of Organization Exempt from Income Tax which is an informational return only.

Barrett is organized as limited liability company, whereby net taxable income is taxed directly to the members and not Barrett. Thus, the consolidated financial statements do not include any provision for Federal or State income taxes. Barrett has filed its federal and state income tax returns for periods through December 31, 2019.

Accounting principles generally accepted in the United States of America require management to evaluate tax positions taken by the Corporation and recognize a tax liability if the Corporation has taken an uncertain position that more likely than not would not be sustained upon examination by various federal and state taxing authorities. Management has analyzed the tax positions taken by the Corporation, and has concluded that as of June 30, 2020 and 2019, there are no uncertain positions taken or expected to be taken that would require recognition of a liability or disclosure in the accompanying consolidated financial statements. The Corporation is subject to routine audits by taxing jurisdictions; however, there are currently no audits for any tax periods in progress. These income tax returns are generally open to examination by the relevant taxing authorities for a period of three years from the later of the date the return was filed or its due date (including approved extensions).

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2020 AND 2019

#### **Subsequent Events**

The Corporation has evaluated events or transactions occurring subsequent to the consolidated balance sheet date for recognition and disclosure in the accompanying consolidated financial statements through the date the consolidated financial statements were issued which was October 15, 2020.

#### **Going Concern Evaluation**

Management evaluates whether there are conditions or events that raise substantial doubt about the Corporation's ability to continue as a going concern for a period of one year from the date the consolidated financial statements were issued.

#### **Recently Issued Accounting Standards**

In February 2016, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2016-02, *Leases (Topic 842)*. This new standard, which the Corporation is not required to adopt until its fiscal year ending June 30, 2021, is intended to improve financial reporting about leasing transactions by requiring entities that lease assets to recognize on their balance sheet the assets and liabilities for the rights and obligations created by those leases, and to provide additional disclosures regarding the leases. Leases with terms (as defined in the ASU) of twelve months or less are not required to be reflected on an entity's balance sheet.

The Corporation is presently evaluating the effects that this ASU will have on its future financial statements, including related disclosures.

#### 2. CHANGE IN ACCOUNTING PRINCIPLES

#### ASU 2018-08

Effective July 1, 2019, the Corporation adopted FASB ASU No. 2018-08, Clarifying the Scope and the Accounting Guidance for Contributions Received and Contributions Made as topic 958 (ASU 2018-08). ASU 2018-08 clarifies and improves current guidance about whether a transfer of assets (or the reduction, settlement, or cancellation of liabilities) is a contribution or an exchange transaction. The amendments clarify how an entity determines whether a resource provider is participating in an exchange transaction by evaluating whether the resource provider is receiving commensurate value in return for the resources transferred.

Additionally, the amendments in this ASU require that an entity determine whether a contribution is conditional on the basis of whether an agreement includes a barrier that must be overcome and either a right of return on assets transferred or a right of release of a promisor's obligation to transfer assets. Finally,

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2020 AND 2019

ASU 2018-08 amends the "simultaneous release accounting policy" to allow a not-for-profit entity to recognize a restricted contribution directly in net assets without donor restrictions if the restriction is met in the same period that revenue is recognized. The adoption of ASU 2018-08 did not have a material impact on the 2020 consolidated financial statements.

#### ASU 2016-01

On July 1, 2019, the Corporation adopted FASB ASU No. 2016-01, Financial Instruments—Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities (ASU 2016-01) which affects all entities that hold financial assets or owe financial liabilities. The guidance in ASU 2016-01 supersedes the guidance to classify equity securities with readily determinable fair values into different categories (that is, trading or available-for-sale) and requires equity securities (including other ownership interests, such as partnerships, unincorporated joint ventures, and limited liability companies) to be measured at fair value with changes in the fair value recognized through the excess revenues over expenses. An entity's equity investments that are accounted for under the equity method of accounting or result in consolidation of an investee are not included within the scope of this guidance. The amendments allow equity investments that do not have readily determinable fair values to be remeasured at fair value either upon the occurrence of an observable price change or upon identification of an impairment. The amendments also require enhanced disclosures about those investments. This ASU does not have a material effect on the Corporation's consolidated financial position, results of operations, or disclosures in the notes to the consolidated financial statements. The primary impact on the Corporation is that changes in the fair value of equity investments will be recognized within the performance indicator, excess revenues over expenses, rather than below the performance indicator where it was previously presented.

#### 3. PATIENT SERVICE REVENUE

The Corporation's revenues generally relate to contracts with patients in which the Corporation's performance obligations are to provide health care services to the patients. Patient service revenue is reported at the amount that reflects the consideration to which the Corporation expects to be entitled in exchange for providing patient care. These amounts are due from patients, third-party payors (including health insurers and government programs), and others and includes variable consideration for retroactive revenue adjustments due to settlement of audits, reviews, and investigations. Generally, the Corporation bills the patients and third-party payors several days after the services are performed or the patient is discharged from the facility. Revenue is recognized as performance obligations are satisfied.

Performance obligations are determined based on the nature of the services provided by the Corporation. Revenue for performance obligations satisfied over time is recognized based on actual charges incurred in relation to total expected (or actual) charges. The Corporation believes that this method provides a faithful depiction of the transfer of services over the term of the performance obligation based on the inputs needed to satisfy the obligation.

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2020 AND 2019

Generally, performance obligations satisfied over time relate to patients receiving inpatient acute care services or patients receiving services in our outpatient centers or in their homes (home care).

The Corporation measures the performance obligation from admission into the Corporation, or the commencement of an outpatient service, to the point when it is no longer required to provide services to that patient, which is generally at the time of discharge or completion of the outpatient services. Revenue for performance obligations satisfied at a point in time is generally recognized when goods are provided to patients and the Corporation does not believe it is required to provide additional goods or services related to that obligation.

Because all of its performance obligations relate to contracts with a duration of less than one year, the Corporation has elected to apply the optional exemption provided in FASB ASC 606-10-50-14a and, therefore, is not required to disclose the aggregate amount of the transaction price allocated to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting period. The unsatisfied or partially unsatisfied performance obligations referred to previously are primarily related to inpatient acute care services at the end of the reporting period. The performance obligations for these contracts are generally completed when the patients are discharged, which generally occurs within days or weeks of the end of the reporting period.

The Corporation determines the transaction price based on standard charges, reduced by contractual adjustments provided to third-party payors, discounts provided to uninsured patients in accordance with the Corporation's policy, and implicit price concessions provided to uninsured patients. The Corporation determines its estimates of contractual adjustments and discounts based on contractual agreements, its discount policies, and historical experience. The Corporation determines its estimate of implicit price concessions based on its historical collection experience with this class of patients. The Corporation continually reviews the contractual estimation process to consider and incorporate updates to laws and regulations and changes in contractual terms.

Agreements with third-party payors typically provide for payments at amounts less than established charges. A summary of the payment arrangements with major third-party payors follows:

- Medicare: Certain inpatient acute care services are paid at prospectively determined rates per discharge based on clinical, diagnostic, and other factors. Certain services are paid based on cost-reimbursement methodologies subject to certain limits. Physician services are paid based upon established fee schedules. Outpatient services are paid using prospectively determined rates.
- Medicaid: Reimbursements for Medicaid services are generally paid at prospectively determined rates per discharge, per occasion of service, or per covered member.
- Other: Payment agreements with certain commercial insurance carriers, health maintenance organizations, and preferred provider organizations provide for payment using prospectively determined rates per discharge, discounts from established charges, and prospectively determined daily rates.

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2020 AND 2019

Laws and regulations concerning government programs, including Medicare and Medicaid, are complex and subject to varying interpretation. As a result of investigations by governmental agencies, various health care organizations have received requests for information and notices regarding alleged noncompliance with those laws and regulations, which, in some instances, have resulted in organizations entering into significant settlement agreements. Compliance with such laws and regulations may also be subject to future government review and interpretation, as well as significant regulatory action, including fines, penalties, and potential exclusion from the related programs. There can be no assurance that regulatory authorities will not challenge the Corporation's compliance with these laws and regulations, and it is not possible to determine the impact (if any) such claims or penalties would have upon the Corporation. In addition, the contracts the Corporation has with commercial payors also provide for retroactive audit and review of claims.

Settlements with third-party payors for retroactive adjustments due to audits, reviews, or investigations are considered variable consideration and are included in the determination of the estimated transaction price for providing patient care. These settlements are estimated based on the terms of the payment agreement with the payor, correspondence from the payor, and the Corporation's historical settlement activity, including an assessment to ensure that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the retroactive adjustment is subsequently resolved. Estimated settlements are adjusted in future periods as adjustments become known (that is, new information becomes available), or as years are settled or are no longer subject to such audits, reviews, and investigations. Adjustments arising from a change in the transaction price were not significant in 2020 or 2019.

Generally, patients who are covered by third-party payors are responsible for related deductibles and coinsurance, which vary in amount. The Corporation also provides services to uninsured patients, and offers those uninsured patients a discount, either by policy or law, from standard charges. The Corporation estimates the transaction price for patients with deductibles and coinsurance and from those who are uninsured based on historical experience and current market conditions. The initial estimate of the transaction price is determined by reducing the standard charge by any contractual adjustments, discounts, and implicit price concessions. Subsequent changes to the estimate of the transaction price are generally recorded as adjustments to patient service revenue in the period of the change. The amounts recognized due to changes in its estimates of explicit and implicit price concessions for the years ended June 30, 2020 and 2019 are not significant. Subsequent changes that are determined to be the result of an adverse change in the patient's ability to pay are recorded as bad debt expense.

Consistent with the Corporation's mission, care is provided to patients regardless of their ability to pay. Therefore, the Corporation has determined it has provided implicit price concessions to uninsured patients and patients with other uninsured balances (for example, copays and deductibles).

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2020 AND 2019

The implicit price concessions included in estimating the transaction price represent the difference between amounts billed to patients and the amounts the Corporation expects to collect based on its collection history with those patients. Implicit price concessions were approximately \$11,800,000 and \$13,582,000 for the years ended June 30, 2020 and 2019, respectively.

Patients who meet the Corporation's criteria for charity care are provided care without charge or at amounts less than established rates. Such amounts determined to qualify as charity care are not reported as revenue.

The Corporation has determined that the nature, amount, timing, and uncertainty of revenue and cash flows are affected by payors. The following tables provide details of this factor.

	2020	 2019
Medicare	\$ 76,031,867	\$ 77,194,507
Medicaid	19,814,328	20,117,319
Commercial and other	127,995,893	129,953,141
Patients	638,887	 648,657
	\$ 224,480,976	\$ 227,913,624

Revenue from patient's deductibles and coinsurance are included in the preceding categories based on the primary payor.

The Corporation participates in the State of Indiana's Hospital Assessment Fee (HAF) Program. The purpose of the HAF Program is to fund the State share of enhanced Medicaid payments and Medicaid Disproportionate Share (DSH) payments for Indiana hospitals as reflected in the HAF Program expense reported in the statements of operations and changes in net assets. Previously, the State share was funded by governmental entities through intergovernmental transfers. The Medicaid enhanced payments relate to both fee for service and managed care claims.

The Medicaid enhanced payments are designed to follow the patients and result in increased Medicaid rates. Beginning July 1, 2017, hospitals also started funding the Healthy Indiana Plan (HIP), the State's Medicaid expansion program. The payments related to the HIP program mirror the Medicaid payments under the HAF program but the funding includes physician, state administration, and certain non-hospital expenditures.

During 2020 and 2019, the Corporation recognized HAF and HIP Program expenses of approximately \$10,075,000 and \$9,842,000, respectively, which resulted in increased Medicaid reimbursement. The HAF and HIP assessments are included in the consolidated statements of operations and changes in net assets as in operating expenses. The Medicaid rate increases under the HAF Program and the HIP payments are included in patient service revenue in the statements of operations and changes in net assets.

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2020 AND 2019

Reimbursement from the Medicare and Medicaid programs is determined from annual cost reports, which are subject to audit by the programs. The Corporation's management believes that amounts recorded in the consolidated financial statements for estimated settlements will approximate the final settlements for open cost reports. The Corporation's cost reports have been audited by the government or its agents and settled through June 30, 2017.

#### 4. INVESTMENTS AND ASSETS LIMITED AS TO USE

The composition of investments and assets limited as to use at June 30 is set forth below:

	2020		2019	
Investments				
Cash equivalents	\$	898,633	\$	179,906
U.S. government obligations		5,240,885		4,493,506
Corporate obligations		4,109,646		2,037,999
		10,249,164		6,711,411
Board designated funds				
Certificates of deposit and cash equivalents		6,162,702		952,932
Mutual funds		56,381,510		55,165,990
U.S. government obligations		12,469,008		15,140,726
Corporate obligations		6,528,303		7,857,243
Limited partnership funds		7,195,741		8,403,706
		88,737,264		87,520,597
Trustee held funds				
Cash equivalents		812		93,182
Donor restricted funds and investments				
held by Foundation				
Cash equivalents		3,668,280		1,665,992
Common stocks		2,781,499		3,022,669
Mutual funds		506,546		826,832
Corporate obligations		1,247,703		770,332
U.S. government obligations		1,186,222		1,118,218
Other		3,105		3,533
		9,393,355		7,407,576
	\$	108,380,595	\$	101,732,766

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2020 AND 2019

The composition of investment return recognized in the consolidated statements of operations and changes in net assets follows:

	 2020	2019
Interest and dividend income	\$ 2,584,656	\$ 2,735,170
Realized gains on sale of investments	529,322	326,018
Realized losses on sale of investments	(458,592)	(215,795)
Unrealized gains (losses) on investments	 (389,367)	1,610,137
Investment income, net	\$ 2,266,019	\$ 4,455,530

The Corporation's investments are exposed to various risks such as interest rate, market and credit. Due to the level of risk associated with these securities and the level of uncertainty related to changes in the value, it is at least reasonably possible that changes in the various risk factors will occur in the near term that could materially affect the amounts reported in the accompanying consolidated financial statements.

#### 5. FAIR VALUE MEASUREMENTS

Effective July 1, 2019, the Corporation adopted FASB ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement. The amendments in this ASU removed and modified certain disclosure requirements in Topic 820. As such, the fair value measurement disclosures for 2019 have been restated for these changes.

The framework for measuring fair value provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1) and the lowest priority to unobservable inputs (level 3). The three levels of the fair value hierarchy are described as follows:

- Level 1: Inputs to the valuation methodology are unadjusted quoted prices for identical assets or liabilities in active markets that the Corporation has the ability to access.
- Level 2: Inputs to the valuation methodology include quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in inactive markets; inputs other than quoted prices that are observable for the asset or liability; inputs that are derived principally from or corroborated by observable market data by correlation or other means. If the asset or liability has a specified (contractual) term, the level 2 input must be observable for substantially the full term of the asset or liability.
- Level 3: Inputs to the valuation methodology are unobservable and significant to the fair value measurement.

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2020 AND 2019

The asset or liability's fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Valuation techniques maximize the use of relevant observable inputs and minimize the use of unobservable inputs.

Following is a description of the valuation methodologies used for assets measured at fair value. There have been no changes in the methodologies used at June 30, 2020 and 2019.

- Common stocks: Valued at the closing price reported on the active market on which the individual securities are traded.
- Mutual funds: Valued at the daily closing price as reported by the fund. Mutual funds held
  by the Corporation are open-end mutual funds that are registered with the Securities and
  Exchange Commission. These funds are required to publish their daily net asset value
  (NAV) and to transact at that price. The mutual funds held by the Corporation are
  deemed to be actively traded.
- Money market funds: Generally transact subscription and redemption activity at a \$1 stable NAV; however, on a daily basis the funds are valued at their daily NAV calculated using the amortized cost of the securities held in the fund.
- *U.S. government obligations*: Valued using pricing models maximizing the use of observable inputs
- Corporate obligations: Valued using pricing models maximizing the use of observable inputs for similar securities. This includes basing value on yields currently available on comparable securities of issuers with similar credit ratings.
- by the investment manager, is used as a practical expedient to estimate fair value. The limited partnership funds consist of investments in a variety of domestic and foreign equity and debt securities, managed accounts and other investment vehicles that employ diversified styles and strategies. The NAV is based on the fair value of the underlying investments held by the fund less its liabilities. Due to the nature of the investments held by the fund, changes in market conditions and the economic environment may significantly impact the NAV of the fund and, consequently, the fair value of the Corporation's interests in the funds. Although a secondary market exists for these investments, it is not active and individual transactions are typically not observable. When transactions do occur in this limited secondary market, they may occur at discounts to the reported NAV. It is therefore reasonably possible that if the Corporation were to sell these investments in the secondary market, a buyer may require a discount to the reported NAV, and the discount could be significant.

# NOTES TO CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2020 AND 2019

The following tables sets forth by level, within the hierarchy, the Corporation's assets and liabilities measured at fair value on a recurring basis as of June 30, 2020 and 2019 are as follows:

	June 30, 2020						
	Total	Level 1	Level 2	Level 3			
Assets							
Investments and assets limited as to use							
Common stocks							
Materials	\$ 91,082	\$ 91,082	\$ -0-	\$ -0-			
Industrials	76,525	76,525	-0-	-0-			
Consumer discretionary	318,154	318,154	-0-	-0-			
Energy	45,006	45,006	-0-	-0-			
Finance	298,238	298,238	-0-	-0-			
Health care	441,372	441,372	-0-	-0-			
Information technology	1,045,302	1,045,302	-0-	-0-			
Services	258,927	258,927	-0-	-0-			
Other	206,893	206,893	-0-	-0-			
Mutual funds							
Value	9,344,015	9,344,015	-0-	-0-			
Blended	12,520,068	12,520,068	-0-	-0-			
Growth	7,047,448	7,047,448	-0-	-0-			
Fixed income	27,976,525	27,976,525	-0-	-0-			
U.S. government obligations	18,896,115	-0-	18,896,115	-0-			
Corporate obligations							
Financial	7,779,979	-0-	7,779,979	-0-			
Consumer	4,105,673	-0-	4,105,673	-0-			
Other	3,105	-0-	3,105	-0-			
		\$ 59,669,555	\$ 30,784,872	\$ -0-			
Certificates of deposit and cash equivalents	10,730,427						
Limited partnership funds (a)	7,195,741						
Total investments and assets limited as to use	\$108,380,595						

# NOTES TO CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2020 AND 2019

	June 30, 2019					
	Total	Level 1	Level 2	Level 3		
Assets						
Investments and assets limited as to use						
Common stocks						
Materials	\$ 205,907	\$ 205,907	\$ -0-	\$ -0-		
Industrials	78,509	78,509	-0-	-0-		
Consumer discretionary	207,792	207,792	-0-	-0-		
Energy	148,269	148,269	-0-	-0-		
Finance	417,217	417,217	-0-	-0-		
Health care	502,019	502,019	-0-	-0-		
Information technology	849,739	849,739	-0-	-0-		
Services	422,913	422,913	-0-	-0-		
Other	190,304	190,304	-0-	-0-		
Mutual funds						
Value	10,083,381	10,083,381	-0-	-0-		
Blended	12,124,533	12,124,533	-0-	-0-		
Growth	7,148,141	7,148,141	-0-	-0-		
Fixed income	26,636,767	26,636,767	-0-	-0-		
U.S. government obligations	20,752,450	-0-	20,752,450	-0-		
Corporate obligations						
Financial	5,910,162	-0-	5,910,162	-0-		
Consumer	4,755,412	-0-	4,755,412	-0-		
Other	3,533	-0-	3,533	-0-		
		\$ 59,015,491	\$ 31,421,557	\$ -0-		
Certificates of deposit and cash equivalents	2,892,012					
Limited partnership funds (a)	8,403,706					
Total investments and assets limited as to use	\$101,732,766					

<sup>(</sup>a) In accordance with Subtopic 820-10, certain investments that were measured at NAV per share or its equivalent have not been classified in the fair value hierarchy. The fair value amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the line items presented at fair value in the consolidated balance sheets.

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2020 AND 2019

The Corporation holds investments which are exposed to various risks such as interest rate, market, and credit. Due to the level of risk associated with these securities and the level of uncertainty related to changes in the value, it is at least reasonably possible that changes in the various risk factors will occur in the near term that could materially affect the amounts reported in the accompanying financial statements.

#### Fair Value of Investments in Entities that Use Net Asset Value

			June 30, 2020			
				Unfunded	Redemption	Redemption
Assets limited as to use		air Value	Subscription	Commitments	Frequency	Notice Period
						Full liquidity mode
Limited partnership - pooled investments	\$	28,190	None	None	Quarterly	to distribute over
						next few quarters
						Full liquidity mode
Limited partnership - pooled investments		180,506	None	None	Quarterly	to distribute over
						next few quarters
Limited partnership - pooled investments		4,498,937	None	None	None	None
Limited partnership - energy		421,663	None	647,822	Illiquid	None
Limited partnership - real estate		1,294,451	None	93,556	Illiquid	None
Limited partnership - secondary		771,994	None	625,194	Illiquid	None
	\$	7,195,741	•			
			June 30, 2019			
				Unfunded	Redemption	Redemption
Assets limited as to use	F	air Value	Subscription	Commitments	Frequency	Notice Period
Limited partnership - pooled investments	\$	974,666	None	None	Quarterly	155 Days
						Full liquidity mode
		767,099	None	None	Quarterly	to distribute over
Limited partnership - pooled investments						next few quarters
Limited partnership - pooled investments		4,485,001	None	None	None	None
Limited partnership - energy		515,866	None	758,385	Illiquid	None
Limited partnership - real estate		1,218,104	None	173,818	Illiquid	None
Limited partnership - secondary		442,970	None	887,555	Illiquid	None
•	\$	8,403,706	•			

# NOTES TO CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2020 AND 2019

#### 6. LONG-TERM DEBT

Long-term debt consists principally of tax-exempt revenue bonds as follows:

	2020	2019
Hospital Authority of the City of Jasper Revenue and Refunding Bonds, Series 2013, commencing December 2013 through November 2035 in amounts ranging from \$1,615,000 to \$4,060,000. Interest payable semiannually between 3.00% and 5.75%	\$ 46,040,000	\$ 47,925,000
Note payable to bank, due August 30, 2020, fixed interest of 2.97%, monthly interest and principle payments		
due in the amount of \$11,435	31,102	164,867
	46,071,102	48,089,867
Original issue premiums (discounts), net	903,675	961,977
	46,974,777	49,051,844
Less current portion	2,011,102	2,019,409
	\$ 44,963,675	\$ 47,032,435

Maturities of long-term debt for the next five years and thereafter are as follows:

Year Ending	
June 30,	
2021	\$ 2,011,102
2022	2,080,000
2023	2,185,000
2024	2,290,000
2025	2,405,000
Thereafter	 35,100,000
	\$ 46,071,102

Interest paid totaled approximately \$2,354,000 and \$2,444,000 in 2020 and 2019, respectively.

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2020 AND 2019

In December 2013, the Hospital Authority of the City of Jasper issued \$56,585,000 (par value) of Fixed Rate Revenue and Refunding Bonds, Series 2013 (the Series 2013 Bonds), dated December 31, 2013, on behalf of the Corporation. A portion of the proceeds of the Series 2013 Bonds were used for the purpose of refunding the previously held Series 2002 Bonds and the Series 2008 Bonds. In addition, the remaining portion of the Series 2013 Bonds, as of June 30, 2020, are being held for the purpose of financing a portion of the costs of construction, equipping, and renovation and improvement of certain facilities of the Corporation.

The Series 2013 Bonds are collateralized by a security interest in substantially all assets of the Corporation and all proceeds therefrom, with the exception of donor-restricted contributions. The note payable to bank is secured by real property with a net book value of approximately \$575,000 as of June 30, 2020.

The Corporation has agreed to certain covenants, which, among other things, limit additional indebtedness and guarantees and require the Corporation to maintain specific financial ratios. Management believes they are in compliance with the covenants at June 30, 2020 and 2019.

#### 7. RETIREMENT PLANS

The Corporation participates in a non-contributory defined benefit pension plan (Plan) which covers the Sisters of the American Province, Little Company of Mary Hospital and Health Care Centers (Illinois), and substantially all employees of the Corporation. Benefits are based upon years of service with the Corporation and annual compensation levels.

In May of 2012, the Corporation's Board of Directors approved a resolution to freeze the defined benefit plan effective December 31, 2012. The effect of this was to stop the accrual of future benefits under the plan. Furthermore, no future employees or currently inactive plan participants will become active plan participants. All active plan participants became fully vested, no future accrual service will be or was credited and no future changes in compensation will be or was taken into account in determining a participant's accrued benefits. Effective October 31, 2017, the Corporation's Board of Directors elected to terminate the defined benefit plan and all obligations were settled prior to June 30, 2019. As a result, the Corporation recognized a loss on pension termination of approximately \$2,751,000 during 2019.

The Corporation adopted the provisions of accounting standards relating to defined benefit pension and other postretirement plans. These standards require employers to recognize in their balance sheets the overfunded or underfunded status of defined benefit plans, measured as the difference between the fair value of plan assets and the projected benefit obligation based upon a measurement date of June 30, 2020 and 2019, respectively.

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2020 AND 2019

The following table sets forth the Plan's funded status and amounts allocated to the Corporation recognized in the financial statements at June 30, 2020 and 2019:

	2020		2019	
Change in benefit obligation		_		
Benefit obligation at beginning of year	\$	-0-	\$	54,309,835
Employee contributions		-0-		-0-
Service cost		-0-		-0-
Interest cost		-0-		791,520
Actuarial losses (gains)		-0-		(483,675)
Benefit payments		-0-		(54,617,680)
Projected benefit obligation at end of year		-0-		-0-
Changes in plan assets				
Fair value of plan assets at beginning of year		2,372,782		56,956,058
Actual return on plan assets		-0-		148,242
Hospital contributions		-0-		-0-
Employee contributions		-0-		-0-
Actual expenses paid		-0-		(113,838)
Benefit payments		-0-		(54,617,680)
Fair value of plan assets at end of year		2,372,782		2,372,782
Funded status				
Funded status of the plan, end of year	\$	2,372,782	\$	2,372,782

During 2019, a lump sum payment was offered in lieu of annuities to all participating employees in the Plan as part of the termination. Approximately \$54,618,000 of lump sum payments were made during 2019 and are included as a component of benefits paid in the table above. No such payments were made during 2020. The Corporation intends to make final lump sum payments during 2021.

# NOTES TO CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2020 AND 2019

Other pension disclosures for 2020 and 2019 include:

	2020		2019	
Amounts not yet reflected in net periodic				
benefit cost and included in other				
changes in net assets without restrictions				
Transition obligation asset (obligation)	\$	-0-	\$	-0-
Prior service cost		-0-		-0-
Actuarial loss		-0-		-0-
Other changes in net assets without restrictions	\$	-0-	\$	-0-
Components of net periodic benefit cost				
Service cost	\$	-0-	\$	-0-
Interest cost		-0-		791,520
Expected return on plan assets		-0-		(679,700)
Net amortization and deferral		-0-		-0-
Settlement/curtailment expense		-0-		2,750,789
Net periodic benefit cost	\$	-0-	\$	2,862,609
Other changes in net assets without restrictions				
Prior service cost arising during year	\$	-0-	\$	-0-
Net gain arising during year		-0-		161,620
Amortization of loss		-0-		-0-
Curtailment/settlement loss		-0-		(2,750,789)
Total other changes in net assets without restrictions	\$	-0-	\$	(2,589,169)
Amounts expected to be amortized from other				
changes in net assets without restrictions over				
the next fiscal year				
Amortization of transition (obligation) asset	\$	-0-	\$	-0-
Amortization of prior service cost	\$	-0-	\$	-0-
Actuarial loss	\$	-0-	\$	-0-
Weighted average actuarial assumptions to				
Weighted-average actuarial assumptions to determine net periodic pension cost as of June 30				
Discount rate	No	t applicable		4.00%
Expected long-term rate of return on assets		t applicable t applicable		3.25%
Rate of compensation increase		t applicable	No	ot applicable
Weighted-average actuarial assumptions to				
determine benefit obligation cost as of June 30				
Discount rate	No	t applicable		4.07%
Expected long-term rate of return on assets		t applicable		3.25%
Rate of compensation increase		t applicable	No	ot applicable
Additional year end information				
Projected benefit obligation	\$	-0-	\$	-0-
Accumulated benefit obligation	\$	-0-	\$	-0-
Fair value of plan assets	\$	2,372,782	\$	2,372,782

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2020 AND 2019

Determination of net periodic pension cost for the years ended June 30, 2020 and 2019 is based on assumptions and census data as of January 1, 2020 and 2019, respectively.

The principal long-term determinant of a portfolio's investment return is its asset allocation. In addition, active management strategies have added value relative to passive benchmark returns. The expected long-term rate of return assumption is based on the mix of assets in the plan, the long-term earnings expected to be associated with each asset class, and the additional return expected through active management. This assumption is periodically benchmarked against peer plans.

The Plan's weighted-average, asset allocations as of June 30, 2020 and 2019, by asset category, are as follows:

	2020	2019
Cash and cash equivalents	100%	0%
Equity funds	0%	18%
Fixed income funds	0%	82%
	100%	100%

The Plan's assets are invested in a portfolio that provides for asset allocation strategies across equity markets, both domestic and international, and debt markets. The portfolio's objective is to maximize the Plan's surplus, minimize annual contributions, and fund the annual interest credit. Management and its investment advisor have prepared asset allocation recommendations based on detailed analyses of the Plan's current and expected future financial needs. Based upon these analyses and objectives of the Plan, the following is the target asset allocation:

	2020	2019
Cash and cash equivalents	100%	0%
Equity funds	0%	20%
Fixed income and other funds	0%	80%
	100%	100%

### NOTES TO CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2020 AND 2019

Following is an analysis of the fair value of major classes of Plan assets as of June 30, 2020 and 2019:

				June 30	0, 202	20		
		Total		Level 1		Level 2		Level 3
Asset category								
Cash and cash equivalents	\$	2,372,782	\$	-0-	\$	2,372,782	\$	-0-
Total plan assets	\$	2,372,782	\$	-0-	\$	2,372,782	\$	-0-
	June 30, 2019							
		Total		Level 1		Level 2		Level 3
Asset category Equity mutual funds	<u></u>	110.500		264040		54640	<u></u>	
Domestic	\$	418,690	\$	364,042	\$	54,648	\$	-0-
Fixed income mutual funds  Domestic		1,954,073		-0-		1,954,073		-0-
Cash and cash equivalents		19		-0-		19		-0-
Total plan assets	\$	2,372,782	\$	364,042	\$	2,008,740	\$	-0-

See Note 5 for a description of the fair value hierarchy that prioritizes the inputs to value techniques used to measure fair value.

The Corporation also maintains 401(k), 403(b) and 457(b) plans for eligible employees. The 403(b) and 457(b) plans do not provide for employer matching contributions from the Corporation. The amount of employer matching contributions for the 401(k) plan is determined each year by the Corporation. The amount of employer matching contributions for the 401(k) plan for the years ended June 30, 2020 and 2019 was approximately \$1,622,000 and \$1,545,000, respectively.

#### 8. FUNCTIONAL EXPENSES

The consolidated financial statements report certain categories of expenses that are attributable to one or more program or supporting functions of the Corporation. Therefore, these expenses require allocation on a reasonable basis that is consistently applied. The expenses that are allocated include depreciation, which is allocated based on square footage, salaries and benefits, which are allocated based on estimates of time and effort, and employee benefits, which are allocated based on a percentage of salaries and benefits.

# NOTES TO CONSOLIDATED FINANCIAL STATEMENTS JUNE 30, 2020 AND 2019

The remaining operating expenses below were allocated based on an identified percentage developed through the Corporation's analysis of indirect cost. Although the methods used were appropriate, alternative methods may provide different results.

The Corporation provides general health care services to patients in the communities in which it operates. Expenses related to providing these services are as follows:

		2020	
	Health care	General &	
	Services	Administrative	Total
Salaries and wages	\$ 87,314,673	\$ 18,399,800	\$ 105,714,473
Employee benefits	17,268,260	3,197,700	20,465,960
Supplies and drugs	36,814,809	563,900	37,378,709
Professional fees	5,463,988	4,045,600	9,509,588
Depreciation and amortization	10,255,044	1,966,000	12,221,044
Purchased services	7,225,648	3,678,400	10,904,048
Hospital assessment fee and healthy Indiana plan	10,075,294	-0-	10,075,294
Interest	2,296,008	-0-	2,296,008
Facility fees and leases	5,522,062	5,915,400	11,437,462
Other	3,716,850	2,946,700	6,663,550
Total expenses	\$ 185,952,636	\$ 40,713,500	\$ 226,666,136
		2019	
	Health care	General &	
	Services	Administrative	Total
Salaries and wages	\$ 84,682,053	\$ 17,845,075	\$ 102,527,128
Employee benefits	21,201,128	3,925,917	25,127,045
Supplies and drugs	36,112,677	553,104	36,665,781
Professional fees	4,899,485	3,627,672	8,527,157
Depreciation and amortization	10,650,693	2,041,890	12,692,583
Purchased services	6,485,126	3,301,388	9,786,514
Hospital assessment fee and healthy Indiana plan	9,842,451	-0-	9,842,451
Interest	2,386,008	-0-	2,386,008
Facility fees and leases	5,703,724	6,110,081	11,813,805
Other	3,659,722	2,901,402	6,561,124
Total expenses	\$ 185,623,067	\$ 40,306,529	\$ 225,929,596

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 2020 AND 2019

#### 9. SELF-INSURED HEALTH AND DENTAL PLAN

The Corporation provides self-insured health and dental benefits to its employees. A third-party claims administrator has been retained to process all benefit claims. Claim expenditures and liabilities are reported when it is probable that a loss has occurred and the amount of the loss can be reasonably estimated. These losses include an estimate of claims that have been incurred but not reported. A stop/loss policy through commercial insurance covers individual claims in excess of \$275,000 per individual per policy year with no aggregate limit. Self-funded health and dental insurance and related expenses were \$11,153,000 and \$15,987,000 for 2020 and 2019, respectively.

#### 10. COMMITMENTS AND CONTINGENCIES

#### **Litigation**

The Corporation is involved in litigation and regulatory matters arising in the course of business. After consultation with legal counsel, management estimates that these matters will be resolved without material adverse effect on the Corporation's future financial position, results from operations and cash flows.

#### **Operating Leases**

Total lease expense for 2020 and 2019 was approximately \$3,347,000 and \$3,721,000, respectively. The Corporation has several non-cancellable operating leases expiring at various dates through 2025.

The future minimum payments due under these leases are as follows:

Year Ending	
June 30,	
2021	\$ 2,834,413
2022	2,517,603
2023	1,600,013
2024	1,236,569
2025	467,810
	\$ 8,656,408

#### **Property and Equipment**

As of June 30, 2020, the Corporation had commitments for property and equipment projects of approximately \$27,745,000, primarily for the Epic electronic health records system and a linear accelerator, through 2021.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 2020 AND 2019

#### 11. INVESTMENT IN JOINT VENTURE

During 2011, the Corporation invested \$60,000 to obtain a 40% interest in the Memorial Hospital Outpatient Surgery Center Management Company, LLC (Management Company) which was formed with the intent to operate a high-quality, cost efficient, outpatient surgery center and to engage in any acts that may be necessary, incidental or convenient to support the surgery center unit of the Corporation. The surgery center department that relates to this management company commenced operations during fiscal year 2013. This 40% interest has been recorded under the equity method of accounting and is located within other assets in the consolidated balance sheets.

As a result of this joint venture, the Corporation recognized a gain during 2020 and 2019 of approximately \$439,000 and \$350,000, respectively, related to changes in equity of the Management Company. The Corporation received dividend distributions during 2020 and 2019 of approximately \$361,000 and \$333,000, respectively. The gain is included within other nonoperating gains in the consolidated statements of operations and changes in net assets.

#### 12. LIQUIDITY AND AVAILABILITY OF RESOURCES

As of June 30, 2020 the Corporation has approximately \$95,213,000 of financial assets available within one year of the consolidated balance sheet date to meet cash needs for general expenditure consisting of cash and cash equivalents of approximately \$63,750,000, investments of approximately \$10,249,000 and accounts receivable of approximately \$21,214,000. As of June 30, 2019, the Corporation had approximately \$72,582,000 of financial assets available within one year of the consolidated balance sheet date to meet cash needs for general expenditure consisting of cash and cash equivalents of approximately \$41,315,000, investments of approximately \$6,711,000 and accounts receivable of approximately \$24,556,000. None of the financial assets are subject to donor or other contractual restrictions that make them unavailable for general expenditure within one year of the consolidated balance sheet date. Accounts receivable are subject to implied time restrictions, but are expected to be collected within one year. The Corporation has a goal to maintain financial assets to meet 90 days of normal operating expenses, which are, on average, approximately \$53,460,000. The Corporation's policy is to structure its financial assets to be available as its general expenditures, liabilities, and other obligations come due. As a part of the Corporation's liquidity management, it has a policy to structure financial assets to be available as its general expenditures, liabilities, and other obligations come due. In addition, the Corporation periodically invests excess cash in investments. The Corporation does not intend to spend from the board designated investments, though these amounts could be made available, if necessary.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
JUNE 30, 2020 AND 2019

#### 13. COVID-19

In March 2020, the World Health Organization declared Coronavirus (COVID-19) a pandemic. The continued spread of COVID-19, or any similar outbreaks in the future, may continue to adversely impact the local, regional, national and global economies. The extent to which COVID-19 continues to impact the Corporation's operating results is dependent on the breadth and duration of the pandemic and could be affected by other factors management is not currently able to predict. Impacts include, but are not limited to, additional costs for responding to COVID-19, potential shortages of healthcare personnel, potential shortages of clinical supplies, loss of, or reduction to, revenue, and investment portfolio declines. Management believes the Corporation is taking appropriate actions to respond to the pandemic. However, the full impact is unknown and cannot be reasonably estimated at the date the consolidated financial statements were issued.

During 2020, Provider Relief Fund (PRF) grants authorized under the Coronavirus Aids, Relief, and Economic Security (CARES) Act were distributed to healthcare providers impacted by the outbreak of the COVID-19 pandemic under Catalog of Federal Domestic Assistance (CFDA) #93.498. Revenues from PRF grants are recognized to the extent the Corporation meets the post-payment reporting requirements, terms and conditions and can be used through June 30, 2021. Funds not used during the term must be returned. The Corporation received PRF grants of approximately \$13,200,000 during 2020 and has recognized approximately \$3,156,000 within other revenue and support in the consolidated statements of operations and changes in nets assets. As of June 30, 2020, \$10,000,000 was recorded as refundable advances within estimated third-party settlements in the consolidated balance sheets.



Blue & Co., LLC / 500 N. Meridian Street, Suite 200 / Indianapolis, IN 46204 main 317.633.4705 fax 317.633.4889 email blue@blueandco.com

# REPORT OF INDEPENDENT AUDITORS ON INTERNAL CONTROL OVER FINANCIAL REPORTING AND ON COMPLIANCE AND OTHER MATTERS BASED ON AN AUDIT OF FINANCIAL STATEMENTS PERFORMED IN ACCORDANCE WITH GOVERNMENT AUDITING STANDARDS

Board of Directors Little Company of Mary Hospital of Indiana, Inc. and Affiliates Jasper, Indiana

We have audited, in accordance with the auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States, the consolidated financial statements of Little Company of Mary Hospital of Indiana, Inc. and Affiliates (the Corporation), which comprise the consolidated statement of financial position as of June 30, 2020, and the related consolidated statements of activities and changes in net assets, and cash flows for the year then ended, and the related notes to the consolidated financial statements, and have issued our report thereon dated October 15, 2020.

#### Internal Control Over Financial Reporting

In planning and performing our audit of the consolidated financial statements, we considered the Corporation's internal control over financial reporting (internal control) to determine the audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the consolidated financial statements, but not for the purpose of expressing an opinion on the effectiveness of the Corporation's internal control. Accordingly, we do not express an opinion on the effectiveness of the Corporation's internal control.

A deficiency in internal control exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A material weakness is a deficiency, or a combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the Corporation's consolidated financial statements will not be prevented, or detected and corrected on a timely basis. A significant deficiency is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Board of Directors Little Company of Mary Hospital of Indiana, Inc. and Affiliates Jasper, Indiana

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses may exist that have not been identified.

#### **Compliance and Other Matters**

As part of obtaining reasonable assurance about whether the Corporation's consolidated financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements, noncompliance with which could have a direct and material effect on the determination of financial statement amounts. However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.

#### Purpose of this Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the entity's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the Corporation's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

Blue & Co., LLC

Indianapolis, Indiana October 15, 2020